Eribulin Mesylate

6 trials 3 recruiting LOncology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

2 Completed trials

6 Sponsors

12 Countries

Phase III

Phase I/II

Phase IV

Phase III: 4 Phase I/II: 1 Phase IV: 1

Indications tested

Breast cancer 4 Breast cancer metastatic 2 Ovarian cancer 1 HER2 positive breast cancer 1 Triple negative breast cancer 1 Breast cancer female 1 Ovarian cancer recurrent 1

Sponsors using this IMP

AstraZeneca AB 2 BioNTech SE 1 Champalimaud Clinical Centre 1 Jazz Pharmaceuticals Ireland Limited 1 Medica Scientia Innovation Research S.L. 1 Rita Fior 1

All trials

6 total

PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR… Pending

2025-524613-89-00 Phase I/II 1 country Medica Scientia Innovation Research S.L.
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 Phase III 8 countries BioNTech SE
zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting

2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Phase III 8 countries Jazz Pharmaceuticals Ireland Limited
A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended

2023-509260-25-00 Phase III 7 countries AstraZeneca AB
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 Phase III 7 countries AstraZeneca AB

Showing 1–6 of 6 trials

← All drugs A–Z